CBER 513(g) Requests

Contains Nonbinding Recommendations

FDA and Industry Procedures for
Section 513(g) Requests for
Information under the Federal Food,
Drug, and Cosmetic Act
Guidance for Industry and
Food and Drug Administration Staff
Document issued on April 6, 2012
The draft of this document was issued on April 29, 2010
This guidance was updated on December 21, 2015 to correct addresses in
Section IV
An agency may not conduct or sponsor, and a person is not required to respond to, a collection
of information unless it displays a currently valid OMB control number. The OMB control
number for this information collection is 0910-0705 (expires 5-31-2018).

See additional PRA statement in Section IX of the guidance.
For questions for the Center for Devices and Radiological Health regarding this document contact
the Premarket Notification (510(k)) Section at 301-796-5640.
For questions for the Center for Biologics Evaluation and Research regarding this document
contact the Office of Communication, Outreach and Development at 1-800-835-4709 or 301-8271800.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health

Contains Nonbinding Recommendations

Center for Biologics Evaluation and Research

Preface
Public Comment
You may submit electronic comments and suggestions at any time for Agency consideration to
http://www.regulations.gov . Submit written comments to the Division of Dockets Management,
Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD
20852. Identify all comments with the docket number FDA- 2012-8226. Comments may not be
acted upon by the Agency until the document is next revised or updated.

Additional Copies
CDRH
Additional copies are available from the Internet. You may also send an e-mail request to
CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document
number 1671 to identify the guidance you are requesting.

CBER
Additional copies are available from the Center for Biologics Evaluation and Research (CBER)
by written request, Office of Communication, Outreach, and Development (OCOD), 10903 New
Hampshire Ave., WO71, Room 3128, Silver Spring, MD 20903, or by calling 1-800-835-4709 or
240-402-7800, by email, ocod@fda.hhs.gov, or from the Internet at
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatio
n/Guidances/default.htm.

Contains Nonbinding Recommendations

Table of Contents
I.
II.
III.
A.
B.
C.
IV.

Introduction .......................................................................................................................................................... 1
Statutory Requirements for Device Classification ................................................................................................ 1
Obtaining Information About a Device ............................................................................................................ 3
General Information .............................................................................................................................................. 3
Section 513(g) Request for Information ............................................................................................................... 3
Formal Jurisdictional Determinations within FDA ............................................................................................... 5
Submitting a 513(g) Request for Information .................................................................................................5

Contains Nonbinding Recommendations

FDA and Industry Procedures for
Section 513(g) Requests for
Information under the Federal Food,
Drug, and Cosmetic Act
Guidance for Industry and
Food and Drug Administration Staff
This guidance represents the current thinking of the Food and Drug Administration (FDA
or Agency) on this topic. It does not establish any rights for any person and is not binding
on FDA or the public. You can use an alternative approach if it satisfies the requirements
of the applicable statutes and regulations. To discuss an alternative approach, contact the
FDA staff or Office responsible for this guidance as listed on the title page.

I.

Introduction

Purpose
The purpose of this guidance is to establish procedures for submitting, reviewing and
responding to requests for information regarding the class in which a device has been
classified or the requirements applicable to a device under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) that are submitted in accordance with section 513(g) of the
FD&C Act, 21 U.S.C. 360c(g).
FDA's guidance documents, including this guidance, do not establish legally enforceable
responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and
should be viewed only as recommendations, unless specific regulatory or statutory
requirements are cited. The use of the word should in Agency guidance means that
something is suggested or recommended, but not required.

II. Statutory Requirements for Device Classification
1

Contains Nonbinding Recommendations

Section 513(a) of the FD&C Act (21 U.S.C. 360c(a)) establishes three classes of devices
based on the regulatory controls needed to provide reasonable assurance of their safety and
effectiveness: class I (general controls), class II (special controls in addition to general
controls), and class III (premarket approval in addition to general controls).
Under section 513(f) of the FD&C Act (21 U.S.C. 360c(f)), post-amendments devices
(devices that were not in commercial distribution before May 28, 1976, the date the Medical
Device Amendments were enacted) are classified in Class III. However, FDA may reclassify
a post- amendments device (as Class I or II) or determine that such a device is "substantially
equivalent" (SE)1 to either another post-amendments device that has been classified into
Class I or II or to a pre-amendments device for which premarket approval is not required2.
Thus, a post-amendments device may be subject to regulation as a Class I or II device in
certain circumstances, including when:
·

the device is within a type of device that has been classified into class I or II and FDA
has found the device to be SE to a device within such type;

·

the device is within a type of pre-amendments device which is to be classified under
section 513(b) of the FD&C Act (21 U.S.C. 360c(b)) and FDA has found the device
to be SE to a device within such type (an unclassified device type); or

·

FDA has classified or reclassified the device type in class I or II in accordance with
sections 513(f)(2) or 513(f)(3) of the FD&C Act (21 U.S.C. 360c(f)(2), (3)).

Pursuant to section 513(d) of the FD&C Act (21 U.S.C. 360c(d)), FDA promulgates
classification regulations classifying devices by generic type. A "generic type of device" is
"a grouping of devices that do not differ significantly in purpose, design, materials, energy
source, function, or any other feature related to safety and effectiveness, and for which
similar regulatory controls are sufficient to provide reasonable assurance of safety and
effectiveness." (See 21 CFR 860.3(i)). FDA has issued regulations classifying the vast
majority of pre- amendments devices (devices that were in commercial distribution before
May 28, 1976) by generic type of device. See 21 CFR 860.84. Each classification
regulation, located at 21 CFR parts 862-892, indicates in which class (I, II, or III) FDA has
1

Substantial equivalence is defined at section 513(i) of the FD&C Act (21 U.S.C. 360c(i)). FDA generally
evaluates substantial equivalence on the basis of a premarket notification submitted pursuant to section 510(k)
of the FD&C Act (21 U.S.C. 360(k)). Certain devices are subject to a statutory exemption from the 510(k)
premarket notification requirement (see sections 510(l) and (m) of the FD&C Act).
2
A pre-amendments device for which premarket approval is not required could be a pre-amendments device that
has been classified into Class I or Class II, a pre-amendments device that has been classified into Class III but for
which a regulation under section 515(b) of the FD&C Act (21 U.S.C. 360e(b)) requiring the submission of an
application for premarket approval (PMA) has not yet been issued, or a pre-amendments device that has not yet
been classified.
2

Contains Nonbinding Recommendations

classified the device type. While the great majority of device classifications codified in 21
CFR parts 862-892 are of pre- amendments devices, some of these classifications are of postamendments devices.

III. Obtaining Information About a Device
A.

General Information

You can obtain information about device classification and regulatory requirements
applicable to a type of device in several ways. FDA's device regulations may be found at 21
CFR parts 800 - 898; the regulations classifying device types are located at 21 CFR parts 862
- 892. The CDRH classification resources on the CDRH web site can help you quickly
ascertain how your device type may be classified. You can also obtain information about the
regulatory requirements that may apply to a particular type of device on FDA’s web site (see
resources below).
·

Product Classification Database

·

510(k) Database

·

Premarket Approval Database

·

Class I and Class II Devices Exempt from 510(k) Requirements

·

Device Guidance Documents

·

Division of Small Manufacturers International and Consumer Assistance
800-638-2041 or 301-796-7100, or by email at DICE@cdrh.fda.gov

·

Office of Combination Products, 301-796-8930, or by email at combination@fda.gov

·

Information regarding particular types of devices regulated by CBER.

If the resources listed above do not address your question, you may contact the premarket
review branch chiefs for more information. Contact information for the Office of Device
Evaluation (ODE) is available at the CDRH Management Directory By Organization (ODE).
Contact information for the Office of In Vitro Diagnostics Evaluation and Safety (OIVD) is
available at the CDRH Management Directory By Organization (OIVD). Contact
information for CBER is available at Contacts in the Center for Biologics Evaluation &
Research (CBER).

B.

Section 513(g) Request for Information
3

Contains Nonbinding Recommendations

Section 513(g) of the FD&C Act (21 U.S.C. 360c(g)) provides a means for obtaining the
agency's views about the classification and the regulatory requirements that may be
applicable to your particular device. This provision states:
Within sixty days of the receipt of a written request of any person for information respecting
the class in which a device has been classified or the requirements applicable to a device
under this Act, the Secretary shall provide such person a written statement of the
classification (if any) of such device and the requirements of this Act applicable to the
device.
Section 513(g) governs requests "for information respecting the class in which a device has
been classified or the requirements applicable to a device under [the] Act." Submissions that
do not request such information are outside the scope of section 513(g).
If, based solely on the information provided with a 513(g) Request for Information, the
product at issue does not appear to be a "device" within the meaning of section 201(h) of the
FD&C Act (21 U.S.C. 321(h)), FDA will so inform the requester in our response. If, based
solely on the information provided with the request, the product does appear to be a "device"
within section 201(h) of the FD&C Act, FDA will generally provide the following
information regarding device classification and applicable FDA regulatory requirements:
·

the agency's assessment, based on the information submitted in the request, as to the
generic type of device (e.g., classification regulation) that the requester's device
appears to be within (if any);

·

the class of devices within that generic type (and if there is more than one class
within that generic type, the particular class within which the requestor's device
appears to fall);

·

whether a PMA, 510(k), or neither is required in order to market devices of the
particular class within that generic type;

·

other requirements applicable to devices of the particular class within that generic
type;

·

whether a guidance document has been issued regarding the exercise of enforcement
discretion over the particular class of devices within that generic type;

·

whether additional FDA requirements may apply, such as those applicable to
radiation-emitting products.

FDA does not review data related to substantial equivalence or safety and effectiveness in a
513(g) Request for Information. FDA's responses to 513(g) Requests for Information are not
device classification decisions and do not constitute FDA clearance or approval for
marketing. Classification decisions and clearance or approval for marketing require
4

Contains Nonbinding Recommendations

submissions under different sections of the FD&C Act. The most common method of
seeking a classification decision is to submit a premarket notification in accordance with
section 510(k) of the FD&C Act (see 21 CFR part 807, subpart E - Premarket Notification
Procedures).
FDA’s response to a 513(g) Request for Information will not address the specific types of
nonclinical, animal, or clinical testing appropriate to support clearance or approval of a
marketing application (when required). You may send a pre-submission to the Document
Control Center for review by the appropriate review branch to receive more specific
information about your specific testing recommendations (for CDRH, see IDE Approval
Process; for CBER, use contact information supplied on the 513(g) Request for Information
response letter).
A 513(g) response does not constitute final Agency action, but provides responsive
information based on the information provided by the requestor.

C.

Formal Jurisdictional Determinations within FDA

If it is unclear to you which Center has jurisdiction over your product, including any
combination product for which the lead Center has not yet been determined, it may be
appropriate to contact the Office of Combination Products (OCP) to discuss your product's
jurisdiction and whether to submit a formal Request for Designation (RFD) under section
563 of the FD&C Act (21 U.S.C. 360bbb-2) rather than submitting a 513(g) Request for
Information. The RFD process is used to obtain a formal agency determination concerning
the classification of a product as a drug, device, biological product, or combination product
subject to section 503(g) of the FD&C Act (21 U.S.C. 353(g)),3 and/or respecting which
agency component(s) will regulate the product.

IV. Submitting a 513(g) Request for Information
A 513(g) Request for Information must be submitted in writing and should be identified as a
513(g) Request for Information.
For submissions to CDRH, two copies of the request should be sent to:
U.S. Food and Drug Administration
Center for Devices and Radiological Health
Document Mail Center – WO66-G609
10903 New Hampshire Avenue
Silver Spring, Maryland 20993-0002
3

Combination product is defined at 21 CFR 3.2(e).
5

Contains Nonbinding Recommendations

For submissions to CBER, two copies of the request should be sent to:
CBER 513(g) Coordinator
Food and Drug Administration
Center for Biologics Evaluation and Research
10903 New Hampshire Avenue
WO71-G112
Silver Spring, MD 20993-0002
User Fees
The Act, as amended by the FDA Amendments Act of 2007 (FDAAA) (Public Law 110-85),
requires FDA to collect user fees for 513(g) Requests for Information. See section
738(a)(2)(A)(ix) of the FD&C Act (21 U.S.C. 379j(a)(2)(A)(ix)). FDA may not accept your
513(g) for review until you have paid all fees owed, including all required establishment
registration fees. See section 738(f)(1) of the FD&C Act (21 U.S.C. 379j(f)(1)). When FDA
has received all fees owed, our review of your 513(g) Request for Information will begin as
of that date.
As explained above, if the submission does not request information respecting the class in
which a device has been classified and/or the requirements applicable to a device under the
Act, it is not a Request for Information governed by section 513(g) of the Act. Such requests
do not require a response from FDA. FDA intends to refund any user fee submitted with a
request that is not governed by section 513(g) of the FD&C Act.
For additional information on user fees for 513(g) requests for information see the guidance
document “User Fees and Refunds for 513(g) Requests for Information.”

V.

Contents of a 513(g) Request for Information

The 513(g) Request for Information should contain the following:
·

a cover letter,

·

a description of the device,4

·

a description of what the device is to be used for, and

·

any proposed labeling or promotional material for the device and, as applicable, any
labeling or promotional material of a similar, legally marketed device, if available.

4

A 513(g) Request for Information should seek classification information and/or regulatory requirements for a
single product and may include multiple uses of the product. Requests for classification information and
regulatory requirements for multiple products should be divided up so that a separate Request for Information
and user fee are submitted for each product.
6

Contains Nonbinding Recommendations

Cover Letter
Your cover letter should identify your request as a “513(g) Request for Information.” Your
cover letter should include:
·

the date of the request,

·

the name of the device,

·

your specific question(s) concerning the class in which a device has been classified
and/or the regulatory requirements applicable to a device,

·

the requestor’s name, address, telephone number, fax number, and email address,5
and

·

the 513(g) requestor’s signature.

Description of the Device
As applicable, the description of the device should include:
·

a list of materials and components used in/with the device,

·

photographs, engineering drawings, and/or samples of the device,6

·

a summary of the device’s operational principles,

·

a description of the type and amount of energy to be used or delivered by the device,
and

·

a description of similar devices in commercial distribution in the United States, if
available.

Device Uses
You should include the following information:
·

the disease or condition with respect to which the device is to be used

·

prescription versus over-the-counter use,

·

part of the body or type of tissue applied to or interacted with,

·

frequency of use,

·

physiological purpose (e.g., removes water from blood, transports blood, etc.),

·

patient population; and

·

any other labeling information related to the patient use of the device.

5

You should provide the contact information for a single point of contact. The contact information should be
associated with the person submitting the Request for Information as the term person is defined in section
201(e) of the FD&C Act.
6
Any sample device can be returned at the request of the submitter.
7

Contains Nonbinding Recommendations

Labeling
You should provide any proposed labeling, including proposed promotional material for the
device or any labeling or promotional material of a similar, legally marketed device. If no
proposed labeling is available for the described device or for a similar legally marketed
device, this should be noted in the cover letter.
Additions to a 513(g) Request for Information
Once FDA has received your 513(g) Request for Information and user fee, you may not
modify that 513(g) request by subsequently adding a new question, use, or technology. We
would consider the addition of a new question, use, or technology to a pending Request for
Information to be a new 513(g) request subject to an additional user fee, to which we intend
to respond separately.

VI. Reviewing a 513(g) Request for Information in
CDRH
Upon receipt of the 513(g) Request for Information and the necessary user fee, the Document
Control Center (DCC) will assign a submission number to the 513(g) Request for
Information and forward the request to a review branch in ODE or OIVD for consideration.
The DCC will send an "acknowledgement of receipt" letter to the submitter of the 513(g)
Request for Information. The 513(g) Request for Information will generally be accepted for
review by a branch in ODE or OIVD. Staff from ODE or OIVD and other Offices within
CDRH with appropriate scientific and regulatory expertise will review the information
provided, meet as necessary, and draft a response for signature by the Director, ODE or
Director, OIVD. The response should be responsive to the regulatory question(s) asked in
the 513(g) Request for Information.

VII. Reviewing a 513(g) Request for Information in CBER
Upon receipt of the 513(g) Request for Information and the necessary user fee, the Document
Control Center (DCC) will forward the submission to the CBER 513(g) Coordinator who
will assign a submission number to the 513(g) Request for Information. The CBER 513(g)
Coordinator will then review the 513(g) Request for Information for completeness, confirm
the request is for information respecting the class in which a device has been classified
and/or the requirements applicable to a device under the FD&C Act, and send an
"acknowledgement of receipt" letter to the submitter of the 513(g) Request for Information.
The 513(g) Request for Information will generally be assigned to one of the product review
offices for consideration. Staff from the assigned product review office and other personnel
within CBER with appropriate scientific and regulatory expertise will review the information
provided, meet as necessary, and draft a response for signature by the director of the assigned
8

Contains Nonbinding Recommendations

product review office. The response should be responsive to the regulatory question(s) asked
in the 513(g) Request for Information.

VIII. Responding to a 513(g) Request for Information in
CDRH or CBER
Our response to a 513(g) Request for Information will be responsive to the questions posed
in the request. We intend to issue our response within 60 days of receipt. Our response will
generally fall into one of the following categories indicating that, based solely on the
information provided in the 513(g) Request for Information; it appears that the product you
have identified is:
·

a device within the meaning of section 201(h) of the FD&C Act, and
o appears to be a an unclassified pre-amendments device type and therefore is
subject to the 510(k) requirement;
o appears to be a post-amendments device type that has not yet been reclassified and therefore is subject to the PMA requirement; or
o appears to be a device that is a classified device type. We will generally
identify the generic type of device (e.g., classification regulation) that your
device appears to be within, the class of devices within which your device
appears to
o fall, and the type of submission, if any, required in order to market devices of
the particular class within that generic type:

·

§

Class I or II subject to the 510(k) requirement;

§

Class I or II exempt from the 510(k) requirement;

§

Class III subject to the 510(k) or PMA requirements; OR

not a device,
o but may be another type of product regulated by FDA. In this case, we would
provide you with contact information for another component within FDA; or
o and appears not to be a product for which FDA has jurisdiction; OR

·

a combination product where it is not clear which Center has primary jurisdiction. If
you would like to discuss further the assignment of this product, we recommend you
contact the Office of Combination Products.

9

Contains Nonbinding Recommendations

If your 513(g) Request for Information is incomplete and we are unable to provide
information regarding classification and/or applicable requirements because you have not
submitted sufficient information to us, we intend to contact the submitter and request
additional information. If FDA does not receive a response within 30 days of our request, we
may consider a 513(g) to be withdrawn. In this instance, FDA may issue a notice of
withdrawal.

IX. Paperwork Reduction Act of 1995
This guidance contains information collection provisions that are subject to review by the
Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44
U.S.C.
3501-3520).
The time required to complete this information collection is estimated to average 12 hours
per response, including the time to review instructions, search existing data sources, gather
the data needed, and complete and review the information collection. Send comments
regarding this burden estimate or suggestions for reducing this burden to:
510(k) Staff, Program Operations Staff, Office of Device Evaluation, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg.
66, Silver Spring, MD 20993.
This guidance also refers to currently approved collections of information found in FDA
regulations. The collections of information in 21 CFR 807 subpart E have been approved
under OMB control number 0910-0120; the collections of information in 21 CFR part 814
have been approved under OMB control number 0910-0231; the collections of information in
21 CFR part 801 have been approved under OMB control number 0910-0485; and the
collections of information in 21 CFR 860.123 have been approved under OMB control
number 0910-0138.

10